CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The new Moderna bivalent vaccine showed higher antibody development vs BA.4/BA.5 than the original version and also showed activity (although lower) against the new BQ1.1 strain. The Pfizer-BioNTech bivalent vaccine generated 3- to 5-fold higher antibody levels than the original vaccine against BA.4/.5 and 11-fold higher levels vs the newer variants.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
